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The aim of this retrospective cohort study
was to analyze the impact of surgery on
the outcomes and qualities of life (QOL)
in patients with intestinal diffuse large
B-cell lymphoma (DLBCL). We assessed
345 patients with either localized or dis-
seminated intestinal DLBCL and com-
pared them according to treatment: surgi-
cal resection followed by chemotherapy
versus chemotherapy alone. In patients
with localized disease (Lugano stage I/II),
surgery plus chemotherapy yielded a
lower relapse rate (15.3%) than did chemo-
therapy alone (36.8%, P < .001). The
3-year overall survival rate was 91% in the
surgery plus chemotherapy group and
62% in the chemotherapy-alone group
(P < .001). The predominant pattern in
the chemotherapy group was local re-
lapse (27.6%). When rituximab was used
with cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone (CHOP), there
was no improvement of the outcomes in
patients treated with primary surgical re-
section. The QOL of patients who under-
went surgery and chemotherapy was
lower than chemotherapy alone, but its
difference was acceptable. Multivariate
analysis showed that surgical resection
plus chemotherapy was an independent
prognostic factor for overall survival. Sur-
gical resection followed by chemotherapy
might be an effective treatment strategy
with acceptable QOL deterioration for lo-
calized intestinal DLBCL. This study was
registered at www.clinicaltrials.gov as
#NCT01043302. (Blood. 2011;117(6):
1958-1965)
Introduction
The small and large intestines are the second most common site of
primary gastrointestinal (GI) lymphomas, and diffuse large B-cell
lymphomas (DLBCL) account for most primary intestinal lympho-
mas.1-3 Considerable information on primary gastric DLBCL is
available, but there are insufficient data on the clinical features and
outcomes of primary intestinal DLBCL because it is usually
studied as a subgroup of GI lymphomas.1,3-5 Although a few reports
focusing on primary intestinal DLBCL have been published,6-9 the
sample sizes were small, and the optimal treatment strategies
specific for primary intestinal DLBCL have not been established.
Various treatment approaches have been tried, such as systemic
chemotherapy similar to that used to treat nodal DLBCL and primary
surgical resection of intestinal lesions and postoperative chemo-
therapy.6,10,11 However, the treatment of primary intestinal DLBCL
is a controversial issue because none of the published studies was
randomized and these studies used mainly Cytoxan, hydroxyrubi-
cin, Oncovin, and prednisone (CHOP) as an adjuvant chemo-
therapy. The combined treatment of rituximab with CHOP (R-
CHOP) is effective for treating nodal DLBCL,12 and R-CHOP
might improve the outcome of primary intestinal DLBCL. Consid-
ering the probability of surgery-related morbidity and subsequent
deterioration of quality of life (QOL), the role of surgery remains to
be determined in the era of rituximab. No reports have compared
the 2 treatment strategies (surgical resection plus chemotherapy
and chemotherapy) in a large study population using rituximab. We
performed a multicenter study to analyze the impact of surgical
resection on the outcomes and QOL of patients and the role of
rituximab in the treatment of intestinal DLBCL.
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Methods
Study design and patients
We performed a retrospective cohort study to assess the clinical features and
outcomes of primary intestinal DLBCL. The clinical data of 345 patients
diagnosed with primary intestinal DLBCL between 1993 and 2009 were
gathered from 16 hospitals affiliated with the Consortium for Improving
Survival of Lymphoma, a Korean lymphoma study group. Pathologic
diagnosis was performed by expert pathologists in lymphoma in each
hospital according to the Revised European-American Lymphoma or the
World Health Organization classifications. The best method for discriminat-
ing primary intestinal DLBCL from systemic DLBCL involving the
intestine is not clear. Patients who presented with predominant intestinal
lesions were classified as having primary intestinal DLBCL according to
the definition proposed in previous reports.13-15
The imaging studies for staging workup were chest and abdomen-pelvis
computerized tomography scans. Not all patients underwent colonoscopy
and esophagogastroduodenoscopy at baseline as a part of the staging
evaluation. Patients were staged according to the Lugano staging system
specified for GI lymphomas.16 Stage I is defined as disease confined to the
intestine, stage II is defined as disease extending to local (II-1) or distant
(II-2) nodes, stage II-E is defined as disease involving adjacent organs or
tissues, and stage IV is defined as disseminated extranodal involvement or
concomitant supradiaphragmatic lymph node involvement. Although the
main analysis was based on a retrospective cohort of primary intestinal
DLBCL, we also performed a concurrent cross-sectional survey of the
QOL of surviving patients from this retrospective cohort at the time of
the study. We surveyed the QOL of 75 patients who had completed their
treatment in one of 8 hospitals. At the time of QOL survey, all survey
participants had completed their treatment and were in a state of
complete response. They provided written informed consent before
answering the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire.17 They answered the question-
naire in reference to their current state.
Analysis of clinical features and outcomes
The treatment strategy was decided by the investigators at each participat-
ing center, except for surgical conditions that needed urgent surgery, such
as perforation or obstruction. We separated patients into 2 groups according
to treatment: surgical resection followed by chemotherapy (surgery/
chemotherapy group) and chemotherapy alone (chemotherapy group)
according to the primary treatment strategy. Surgical resection of a primary
tumor mass, such as hemicolectomy or segmental resection and anastomo-
sis, was performed with or without lymph node dissection. The extent of
lymph node dissection varied between participating centers and included
regional lymph node dissection equivalent to colon adenocarcinoma or
resection only of lymph nodes with suspected lymphoma involvement. We
compared the clinical features of the 2 groups, including the Eastern
Cooperative Oncology Group (ECOG) performance status, serum lactate
dehydrogenase concentration, site of involvement, the International
Prognostic Index (IPI), Lugano stage, and the presence of B symptoms.
Because intestinal involvement itself can cause weight loss, weight loss
without fever and night sweats was not considered as a B symptom.
Bulky disease was defined as the maximum diameter of a mass larger
than 10 cm. To simplify the analysis of response data, the response was
defined according to the World Health Organization criteria as follows.18
Complete response (CR) was designated as the disappearance of all
lesions and absence of any new tumor lesions. Partial response was
defined as a decrease of more than or equal to 50% in each lesion.
Progressive disease or relapse was defined as the presence of a newly
developed lesion or more than 25% increase in the product of
2 diameters of at least one tumor. Stable disease was defined as the state
of neither partial response nor progressive disease.
Cross-sectional assessment of QOL
We compared the QOL of the surgery/chemotherapy and chemotherapy groups.
Linear regression analysis was used to analyze the lymphoma-related factors,
such as IPI, serum lactate dehydrogenase concentration, B symptoms, involved
sites, stage, and patient-related factors, such as age at diagnosis, survival time,
and ECOG performance status, to exclude possible confounding factors that can
affect QOL. Because we hypothesized that surgery might decrease the patients’
QOL, we used a noninferior test with a margin for acceptance of noninferiority as
15% of the difference. Thus, if the lower limit of the 95% confidence interval was
within the margin of 15%, the QOL of patients treated with surgery plus
chemotherapy was interpreted as not inferior to that of the patients treated with
chemotherapy.
Statistical analysis
The 2 test was used to evaluate the relationships between clinical features and
outcomes. Overall survival (OS) was calculated from the date of diagnosis to the
date of the final follow-up or death from any cause. Progression-free survival
(PFS) was from the date of diagnosis to the date of disease progression, relapse,
or death from any cause. Survival was estimated from Kaplan-Meier curves and
compared using the log-rank test. The Cox proportional hazard regression model
was used in the multivariate analysis to identify prognostic factors. A 2-sided
P value less than .05 was considered significant. The institutional review board of
each hospital approved this study, and it was registered at www.clinicaltrials.gov
as #NCT01043302.
Results
Characteristics of patients
The characteristics of the 345 enrolled patients at diagnosis are
summarized in Table 1. The median follow-up duration was
37.7 months (95% confidence interval, 30.19-45.15 months). The
median age was 57 years (range, 15-92 years), and the male-to-
female ratio was 1.63:1. Most patients had good performance status
( ECOG grade 0/1, 83.2%) and localized disease (Lugano stage
I/II, 77.1%) usually involving the ileocecal area. Thus, the IPI risk
was mainly low or low intermediate (75.0%).
More than half of the patients underwent primary surgical
resection, and the main chemotherapy included 6 cycles of
CHOP or R-CHOP. Surgical resection was performed via open
laparotomy, and no patient required permanent or temporary
colostomy because most lesions were around the ileocecum/
ascending colon. In the surgery/chemotherapy group, the me-
dian interval between surgery and chemotherapy was 19.5 days
(range, 14-42 days), although it varied between centers.
Six patients refused treatment and were lost to follow-up early
after diagnosis. Twelve patients underwent only surgery because
they refused further chemotherapy because of old age or poor
performance status. Among these 12 patients, 10 relapsed or
died, and only 2 patients with stage I disease survived to the
time of analysis. Because these 18 patients did not fit one of the
2 strategies we chose to assess (surgery/chemotherapy or
chemotherapy alone), we excluded them from the treatment
outcome analysis. Thus, the treatment outcomes of 327 patients
were compared according to treatment strategy: surgery/
chemotherapy versus chemotherapy alone.
Treatment outcome of localized disease
The surgery/chemotherapy group had more patients with a lower
IPI risk than did the chemotherapy group (P  .006, Table 2).The
number of patients with Lugano stage I and II-1 was nonsignifi-
cantly greater in the surgery/chemotherapy group, although this
was of marginal significance (P  .051, Table 2). The number of
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patients with bulky disease was significantly higher in the surgery/
chemotherapy group (P  .001, Table 2). The number of patients
who received radiotherapy after chemotherapy was higher in the
chemotherapy group, although only a limited number (n 12,
13.8%) of patients received radiotherapy. Other characteristics did
not differ significantly between the 2 groups (Table 2).
The most common reason for surgery was primary mass resection
for both therapeutic and diagnostic purposes. Presentation as bowel
perforation or bleeding was a rare cause for surgery, whereas bowel
obstruction was a frequent cause. Among patients treated initially with
chemotherapy, 8 underwent surgery because of chemotherapy-related
complications, such as perforation (8 of 87, 9.2%), and their median
onset time was 3 days after chemotherapy started (range, 2-7 days).
Four patients underwent surgery because of relapse or progression
during or after chemotherapy (4 of 87, 4.6%).
The CR rate was significantly higher in the surgery/chemo-
therapy group (85.3%) than in the chemotherapy group (64.4%,
P  .001). The relapse rate was lower in the surgery/chemotherapy
group (25 of 163, 15.3%) than in the chemotherapy group (32 of
87, 36.8%). Local relapse, defined as relapse from the primary site
or adjacent sites including regional nodes, was the predominant
pattern of relapse in the chemotherapy group (27.6%, Table 2).
Thus, both the OS and PFS of the surgery/chemotherapy group
were significantly better than those in the chemotherapy-alone
group (Figure 1A,D). The 3-year OS was 91% in the surgery/
chemotherapy group and 62% in the chemotherapy group
(P  .001). In the surgery/chemotherapy group, OS and PFS were
not related to Lugano staging (P  .05), but patients with Lugano
stage IIE had a worse PFS in the chemotherapy group (P  .014).
Because of the differences in IPI scores and Lugano stages between
the surgery/chemotherapy group and the chemotherapy group, we
performed a subgroup analysis to compare patients with localized
disease according to IPI risk category and Lugano stage. In the
subgroup analysis, the OS and PFS were significantly longer in the
surgery/chemotherapy group than in the chemotherapy group
regardless of IPI risk and Lugano stage category (P  .005).
Treatment outcome for disseminated disease
Of the patients with Lugano stage IV, 52 were treated with
chemotherapy, and 7 of these patients received follow-up radio-
therapy (Table 2). Although disease status was disseminated,
25 patients underwent surgery for diagnostic or therapeutic pur-
poses. The characteristics were balanced between the 2 groups, and
the response and relapse rates did not differ between the 2 groups
(Table 2). The 3-year OS rate of disseminated disease was
significantly less than that of localized disease (47% vs 80%).
Comparison of OS and PFS according to the treatment strategy
showed no significant differences between the 2 groups (P  .05,
Figure 2A-B).
Impact of rituximab on the outcome
In patients with localized disease, 69 patients received CHOP
chemotherapy, and 87 patients received R-CHOP after primary
surgical resection. The median number of cycles was 6 in both
regimens, and the characteristics at diagnosis were balanced
between them. However, R-CHOP failed to show a survival benefit
over CHOP (P  .05, Figure 1B,E). Thus, regardless of rituximab
use, the 3-year OS was more than 90% in patients with localized
disease treated with chemotherapy after surgery. In patients with
localized disease treated with chemotherapy alone, OS and
PFS did not differ significantly between CHOP (n  45) and
R-CHOP (n  36) (P  .05, Figure 1C,F). Although a small
number of patients underwent surgery (n  25), there was no
significant difference in survival between patients with dissemi-
nated disease treated with surgery plus CHOP or surgery plus
R-CHOP (P  .05). However, when the OS and PFS were
compared according to the use of rituximab in patients with
disseminated disease, R-CHOP treatment showed an approach-
ing statistical significance for longer OS and PFS than did
Table 1. Characteristics of patients (n  345)
Characteristic/category No. %
Age, y
Median (range) 57 (15-92)
 60 204 59.1
 60 141 40.9
Sex
Male 214 62.0
Female 131 38.0
Performance status
ECOG 0/1 287 83.2
ECOG  2 58 16.8
Serum LDH level
Normal 206 59.7
Increased 133 38.6
Missing 6 1.7
B symptoms
Absent 279 80.9
Present 65 18.8
Missing 1 0.3
Extranodal involvements
 2 267 77.4
 2 78 22.6
IPI
Low/low to intermediate 204/55 59.1/15.9
High to intermediate/high 53/27 15.4/7.8
Missing 6 1.7
Lugano stage
I 78 22.6
II-1 106 30.7
II-2 68 19.7
II-E 14 4.1
IV 79 22.9
Bulky disease
Bulky 73 21.2
Nonbulky 272 78.8
Bone marrow invasion
Absent 306 88.7
Present 16 4.6
Not evaluated 23 6.7
Location
Duodenum 12 3.5
Jejunum/ileum 17/63 4.9/18.3
Ileocecum/ascending colon 175/37 50.7/10.7
Transverse/descending colon 11/3 3.2/0.9
Rectosigmoid colon 14 4.0
Multiple sites 13 3.8
Treatment modality
Surgery/CTx 188 54.5
CTx 139 40.3
Surgery 12 3.5
No treatment 6 1.7
CTx regimen
CHOP 134 38.8
R-CHOP 172 49.9
Others 21 6.1
LDH indicates lactate dehydrogenase; and CTx, chemotherapy.
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CHOP treatment (P  .0678, and .0651, respectively; Figure
2C-D). Thus, the 3-year OS was higher in patients treated with
R-CHOP (59%) compared with CHOP (29%).
Comparison of QOL
All participants answered the questionnaire in reference to their
current QOL in the state of CR; at the time of the QOL survey,
their median follow-up duration after CR was 32.3 months
(range, 7.1-120.3 months). Thus, 64 survivors from 159 alive
patients in the surgery/chemotherapy group participated in the
QOL survey, whereas 11 survivors from 72 alive patients treated
with chemotherapy alone participated (Table 2). When the mean
scores of each parameter were compared between the 2 groups,
the lower limit of 95% confidence interval more than 15% was
Table 2. Comparison of patients based on treatment strategy (n  327)*
Lugano I/II Lugano IV
Surgery/CTx, no.
(%; n  163)
CTx, no.
(%; n  87) P
Surgery/CTx, no.
(%; n  25)
CTx, no.
(%; n  52) P
Age, y
 60 109 (66.9) 49 (56.3) .130 13 (52.0) 25 (48.1) .810
 60 54 (33.1) 38 (43.7) 12 (48.0) 27 (51.9)
Performance status
ECOG 0/1 146 (89.6) 79 (90.8) .828 18 (72.0) 33 (63.5) .608
ECOG  2 17 (10.4) 8 (9.2) 7 (28.0) 19 (36.5)
Lugano stage
I 49 (30.1) 20 (23.0) .051
II-1 70 (42.9) 30 (34.5)
II-2 35 (21.5) 33 (37.9)
II-E 9 (5.5) 4 (4.6)
IPI
Low 134 (83.2) 57 (65.5) .006 1 (4.0) 4 (7.7) .239
Low to intermediate 20 (12.4) 21 (24.1) 6 (24.0) 5 (9.6)
High to intermediate 7 (4.3) 9 (10.3) 12 (48.0) 22 (42.3)
High 0 (0.0) 0 (0.0) 6 (24.0) 21 (40.4)
Missing 2
Primary mass size
Bulky 45 4  .001 13 8 .002
Nonbulky 118 83 12 44
Reason for surgery
Mass resection 98 (60.1) 14 (56.0)
Obstruction 51 (31.3) 8 (32.0)
Bleeding 7 (4.3) 1 (4.0)
Perforation 7 (4.3) 2 (8.0)
Relapse/progression 4 (4.6)
Perforation after CTx 4 (4.6) 2 (3.8)
Other complications after CTx 4 (4.6) 1 (1.9)
Chemotherapy regimen
CHOP 69 (42.3) 45 (51.7) 0.243 5 (20.0) 15 (28.8) .695
R-CHOP 87 (53.4) 36 (41.4) 17 (68.0) 33 (63.5)
Others 7 (4.3) 6 (6.9) 3 (12.0) 4 (7.7)
Radiotherapy
Done 4 (2.5) 12 (13.8) .001 3 (12.0) 7 (13.5)  .99
Not done 159 (97.5) 75 (86.2) 22 (88.0) 45 (86.5)
Response
CR 139 (85.3) 56 (64.4)  .001 13 (52.0) 24 (46.2) .971
PR 2 (1.2) 13 (14.9) 5 (20.0) 13 (25.0)
SD 2 (1.2) 4 (4.6) 1 (4.0) 2 (3.8)
PD 8 (4.9) 9 (10.3) 3 (12.0) 8 (15.4)
NE 12 (7.4) 5 (5.7) 3 (12.0) 5 (9.6)
Relapse/progression
Local 14 (8.6) 24 (27.6)  .001 5 (20.0) 6 (11.5) .454
Systemic 11 (6.7) 8 (9.2) 5 (20.0) 16 (30.8)
None 138 (84.7) 55 (63.2) 15 (60.0) 30 (57.7)
Survival
Alive 143 (87.7) 49 (56.3)  .001 16 (64.0) 23 (44.2) .409
Unknown† 8 (4.9) 7 (8.0) 1 (4.0) 4 (7.7)
Dead 12 (7.4) 31 (35.6) 8 (32.0) 25 (48.1)
3-y PFS 82% 52%  .001 52% 34% .518
3-y OS 91% 62%  .001 58% 44% .303
CTx indicates chemotherapy; PR, partial response; SD, stable disease; PD, progressive disease; and NE, not evaluable.
*Among 345 patients, 12 patients had surgery only and 6 patients received no treatment.
†The survival status was unknown because of follow-up loss. These patients were censored during the Kaplan-Meier survival analysis.
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designated as significant as described in “Cross-sectional assess-
ment of QOL.” Among the parameters of functional scales, the
physical, role, cognitive, and social functioning did not differ,
and only the emotional functioning was worse in the surgery/
chemotherapy group. Among the parameters of symptom scales,
nausea, vomiting, appetite loss, and financial difficulties did not
differ significantly between treatment groups. Although fatigue
was inferior in patients receiving surgery based on the definition
of inferiority, its difference in mean scores was only 1.67 points
(Table 3). However, patients in the surgery/chemotherapy
group were significantly inferior to chemotherapy alone in
the scale of constipation, diarrhea, insomnia, and dyspnea.
As a result, the mean score of global health status was lower in
the surgery/chemotherapy group than chemotherapy group
(Table 3).
Analysis of prognostic factors
Univariate analysis with binary variables showed that age more
than 60 years, performance status more than or equal to ECOG
grade 2, increased serum lactate dehydrogenase level, number of
extranodal involvements more than or equal to 2, Lugano stage IV,
high to intermediate/high IPI risk, and surgery/chemotherapy were
prognostic indicators for OS (P  .05). However, multivariate
analysis, which included all these factors and used IPI risk as a
continuous variable, showed that only treatment strategy based on
primary surgical resection followed by chemotherapy was an
independent prognostic factor for OS (Table 4). When the multivar-
iate analysis was performed separately for localized and dissemi-
nated disease, surgery/chemotherapy was significant only in pa-
tients with localized disease (Table 4).
Discussion
Primary intestinal DLBCL presents mainly as a localized disease,
and the ileocecal area is the most frequently involved site.11,19 Our
patients had mainly localized disease, especially Lugano stages I,
II-1, and II-2 (73.0%). Thus, surgical resection of the primary mass
followed by postoperative chemotherapy, CHOP, or R-CHOP was
performed in more than two-thirds of patients with localized
disease (n 163, Table 2). This combined treatment strategy
produced a 3-year OS rate of more than 90% (Figure 1). Although
the IPI risk was lower in the surgery/chemotherapy group, the
subgroup analysis by IPI risk category also revealed significantly
better outcome in the surgery/chemotherapy group than in the
chemotherapy group within the same IPI risk category (P  .05).
This favorable outcome of surgery/chemotherapy is consistent with
that observed in previous prospective studies reporting prolonged
survival with a low relapse rate in intestinal B-cell lymphomas.10,11
Surgery plus chemotherapy showed a higher CR rate (85.3%) and a
lower relapse rate (15.3%) than the CR (64.4%) and relapse
(36.8%) rate for chemotherapy alone (P  .001). Local relapse was
Figure 1. Survival outcomes were compared in patients with localized disease according to the treatment strategy. Surgical resection followed by chemotherapy
produced significantly longer OS (A) and PFS (D) than chemotherapy alone. In patients treated with primary surgical resection for localized disease, the postoperative
chemotherapy regimen, CHOP or R-CHOP, did not significantly affect OS (B) or PFS (E). In patients treated with chemotherapy alone, OS (C) and PFS (F) did not differ
between patients treated with CHOP or R-CHOP.
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more frequent in the chemotherapy alone group. Although this was
a retrospective study and data were not available regarding the
decision of why patients with localized disease proceeded to
surgery plus chemotherapy versus chemotherapy alone, these
findings suggest that the better outcome in the surgery/chemo-
therapy group might be related to the complete resection of the
bowel segment. Because it can be difficult to discriminate residual
lesions in cases of bowel wall thickening, the underestimation of
residual lesions might be another reason for the higher local relapse
rate in the chemotherapy group.
In primary gastric DLBCL, the role of surgery has diminished,
and treatment strategy has moved toward organ preservation
because surgical resection is not superior to chemotherapy plus
radiotherapy.20,21 The benefit of radiotherapy might be its curative
potential for attacking low-grade lymphoma components because
the presence of low-grade lymphoma components can contribute to
local relapse.22 Unlike gastric DLBCL, the association of low-
grade lymphoma components with the risk of relapse is still
controversial in primary intestinal DLBCL; the presence of low-
grade components is not consistent among previous studies of
intestinal DLBCL.3,19,23 The intestine is less suitable for radio-
therapy than is the stomach. Two specific problems with intestinal
DLBCL (ie, difficulties in preoperative pathologic diagnosis and
the risk of complications requiring surgery) also contribute to the
widespread use of surgical resection for intestinal lymphomas. In
this study, a substantial number of patients (n 65, 39.9%)
underwent surgery before diagnosis because of obstructions and
other complications associated with intestinal lesions.
Surgical resection did not provide any significant benefit to
patients with disseminated disease in our study. Thus, more
effective chemotherapy may produce a better outcome for dissemi-
nated disease, such as nodal DLBCL. Comparison of the outcomes
of CHOP and R-CHOP in these patients showed that R-CHOP had
a longer 3-year OS (59%) compared with CHOP (29%), although
the difference was not statistically significant (P  .0678, Figure
2C). These data suggest that R-CHOP is a better treatment for
disseminated disease. However, the addition of rituximab to CHOP
failed to show additional survival benefits in terms of localized
disease, regardless of surgery (Figure 1B-C,E-F). This suggests
that inclusion of rituximab in the chemotherapy regimen might not
affect the outcome of localized disease as much as we expected. It
also emphasizes the importance of surgical resection to the
prognosis for patients with localized intestinal DLBCL, although
postoperative chemotherapy is the accepted mainstay in the
treatment of this disease.11,23 The value of rituximab cannot be
determined before these findings are confirmed in a randomized
prospective study.
Figure 2. Comparison of survival outcomes in patients with disseminated disease according to the treatment strategy. OS (A) and PFS (B) did not differ between the
surgery/chemotherapy and chemotherapy groups. However, comparison according to the use of rituximab showed longer OS (C) and PFS (D) in patients treated with R-CHOP
than in those treated with CHOP.
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Even though the role of surgery seemed to be important in the
treatment of intestinal DLBCL, surgical resection of the primary
mass has been a topic of debate because DLBCL itself is a
medical disorder that can be cured by chemotherapy. Thus, the
major concern about surgery is the deterioration of QOL. To
address this issue, we assessed the QOL of 75 survivors who
completed their treatment courses. In the comparison of symp-
tom scales, patients who underwent surgery and chemotherapy
were significantly inferior to chemotherapy alone in the scale of
fatigue, constipation, diarrhea, insomnia, and dyspnea, whereas
other GI tract-associated parameters, such as nausea and
vomiting, and appetite loss were not significantly different
(Table 3). The global health status of the surgery/chemotherapy
group was also inferior to the chemotherapy group. However,
the most functional scales did not differ significantly between
the 2 groups. Thus, these results suggest that the surgery-
associated deterioration of QOL may be acceptable, and the
benefits of surgery plus chemotherapy may outweigh this
negative effect of surgery on QOL considering the favorable
outcome of surgery/chemotherapy.
Table 3. Comparison of quality of life
Parameter Mean score* 95% CI for difference (%)†
Interpretation‡Surgery/CTx (n  64) Chemotherapy (n  11) Upper limit Lower limit
Functional scales
Physical functioning 73.53 74.01 11.59 12.55 Not inferior
Role functioning 77.76 75.86 16.64 12.84 Not inferior
Emotional functioning 78.27 87.99 3.44 22.83 Inferior
Cognitive functioning 78.64 79.19 11.44 12.56 Not inferior
Social functioning 79.84 73.44 23.86 11.06 Not inferior
Symptom scales
Fatigue 47.90 46.23 13.34 16.67 Inferior
Nausea and vomiting 1.50 0.01 5.05 8.79 Not inferior
Pain 6.52 14.50 25.14 9.19 Not inferior
Dyspnea 18.01 7.35 8.31 29.63 Inferior
Insomnia 8.95 5.90 17.16 23.27 Inferior
Appetite loss 20.40 24.42 20.31 12.47 Not inferior
Constipation 17.24 10.51 8.07 21.55 Inferior
Diarrhea 38.73 19.87 1.82 39.55 Inferior
Financial difficulties 21.08 28.38 26.64 12.24 Not inferior
Global health status
Global health 61.31 71.50 6.02 26.38 Inferior
*The mean scores for each parameter. The higher scores of functional scales and global health status indicate better function and health status. The lower scores of
symptom scales indicate that patients have fewer symptoms.
†The 95% CI for difference between 2 groups adjusting covariates, such as IPI, serum LDH concentration, B symptoms, involved sites, stage, age at diagnosis, survival
time, and ECOG performance status.
‡If the lower limit of the 95% CI is within the margin of 15%, the parameter of surgery plus chemotherapy can be interpreted as not inferior to that of chemotherapy.
Table 4. Multivariate analysis of prognostic factors for OS
Characteristic Lugano stage I/II Lugano stage IV Total
P Hazard ratio 95% CI P Hazard ratio 95% CI P Hazard ratio 95% CI
Age, y
 60 vs  60 .260 1.917 0.618-5.940 .883 1.116 0.259-4.811 .165 1.823 0.781-4.257
Sex
Male vs female .871 0.938 0.433-2.032 .348 0.620 0.228-1.683 .550 0.836 0.466-1.502
Performance status
ECOG  2 vs  2 .206 2.969 0.549-16.048 .514 1.572 0.405-6.107 .178 1.983 0.732-5.375
Serum LDH level
Normal vs increased .412 1.633 0.507-5.261 .970 1.033 0.190-5.610 .666 1.238 0.469-3.266
B symptoms
Absent vs present .499 1.365 0.553-3.366 .397 0.573 0.158-2.078 .466 1.281 0.659-2.492
No. of extranodal involvements
 2 vs  2 .795 0.817 0.178-3.761 .933 0.932 0.183-4.749 .719 0.827 0.294-2.327
Lugano stage
I/II vs IV .932 1.050 0.345-3.200
IPI
L vs LI vs HI vs H .976 1.022 0.252-4.140 .169 3.271 0.605-17.688 .330 1.640 0.607-4.431
Bone marrow
Normal vs invasive .514 2.130 0.220-20.615 .090 0.340 0.098-1.182 .392 0.639 0.229-1.783
Treatment
Surgery/chemotherapy vs chemotherapy .001 3.963 1.772-8.865 .667 0.761 0.220-2.636 .002 2.845 1.453-5.568
Chemotherapy regimen
R-CHOP vs CHOP .340 0.692 0.325-1.475 .212 1.853 0.704-4.881 .968 1.012 0.564-1.815
CI indicates confidence interval for hazard ratio; LDH, lactate dehydrogenase; L, low; LI, low to intermediate; HI, high to intermediate; and H, high.
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However, a limitation of the QOL comparison in our study
included the number of patients from the chemotherapy group was
lower than the surgery/chemotherapy group, which may have
biased the results. This imbalance of numbers may be in part
associated with that the number of total (163 vs 87) as well as alive
patients (159 vs 72) was much higher in the surgery/chemotherapy
group than the chemotherapy group. Therefore, a prospective study
assessing QOL in the future may help to clarify the effect of surgery
on the QOL of patients in this clinical setting.
Multivariate analysis demonstrated that surgical resection fol-
lowed by chemotherapy was an independent prognostic factor for
OS (Table 4). Because most patients with Lugano stage I/II and low
IPI risk underwent surgery, the prognostic value was diluted in the
multivariate analysis. When the multivariate analysis was done
separately for localized and disseminated disease, the prognostic
value of surgery plus chemotherapy was significant only for
localized disease (Table 4). These findings suggest that patients
with localized disease who are medically fit to undergo surgery
might have better outcomes.
In conclusion, surgical resection followed by chemotherapy
might be recommended as an effective treatment strategy for
localized intestinal DLBCL. Surgery-related deterioration of QOL
might be an acceptable disadvantage of this strategy. Although the
extent of surgery may be associated with the outcome of localized
intestinal DLBCL, this issue should be addressed in a future
prospective study. Our results also challenge the value of rituximab
as a postoperative chemotherapy or primary chemotherapy in
treating localized disease. However, this also needs to be defined in
a prospective randomized study.
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